News

Abbott and Enanta present positive Phase 2 study data

Date: 04/04/2011

Boston, USA – Abbott and Enanta present positive 12-week results and 3-day resistance data from their Phase 2 study of ABT-450/r for the treatment of hepatitis C. Read full article here.